-
公开(公告)号：US20220362204A1
公开(公告)日：2022-11-17
申请号：US17869210
申请日：2022-07-20
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.
-
公开(公告)号：US20200261402A1
公开(公告)日：2020-08-20
申请号：US16794974
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
IPC: A61K31/327 , A61P17/00
Abstract: A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.
-
公开(公告)号：US20200261401A1
公开(公告)日：2020-08-20
申请号：US16794923
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.
-
公开(公告)号：US20230364050A1
公开(公告)日：2023-11-16
申请号：US18225397
申请日：2023-07-24
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
CPC classification number: A61K31/327 , A61K9/50 , A61K9/06 , A61K9/0014 , A61P17/10 , A61K9/107 , A61P17/00 , A61K9/10
Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.
-
公开(公告)号：US20200261400A1
公开(公告)日：2020-08-20
申请号：US16794887
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
IPC: A61K31/327 , A61P17/10 , A61K9/107
Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.
-
Patent Agency Ranking
公开(公告)号：US20200261399A1
公开(公告)日：2020-08-20
申请号：US16794839
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
IPC: A61K31/327 , A61K9/06 , A61K9/107 , A61P17/10
Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
-
公开(公告)号：US20200261397A1
公开(公告)日：2020-08-20
申请号：US16794734
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
IPC: A61K31/327 , A61P17/00 , A61K9/50
Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
-
公开(公告)号：US20230076766A1
公开(公告)日：2023-03-09
申请号：US17892620
申请日：2022-08-22
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
Abstract: A regimen for the therapeutic treatment of rosacea in a subject aged 35-64 years, the regimen comprising topically applying a pharmaceutical composition to the skin of the subject in need of said treatment, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, to achieve, in a group of such subjects, a success rate of at least about 12%, at least about 27%, at least about 38%, or at least about 42%, respectively, and wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
-
公开(公告)号：US20210169841A1
公开(公告)日：2021-06-10
申请号：US17154689
申请日：2021-01-21
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
-
公开(公告)号：US20210145790A1
公开(公告)日：2021-05-20
申请号：US17156941
申请日：2021-01-25
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer TOLEDANO , Ofra LEVY-HACHAM , Ori NOV , Vered RAM
Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.014 seconds)
